Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723071 | 0.76 | F10 (0.55) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7606555 | 0.75 | KCNK3 (0.68) | MEN1KMT2AMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL4724325 | 0.75 | RAB9A (0.49) | MEN1KMT2AMAPTSMN1; SMN2KCNK3 | |
| SCHEMBL4721074 | 0.74 | NR1H4 (0.58) | MAPTSMN1; SMN2RXFP1KCNK3NR1H4 | |
| SCHEMBL12764313 | 0.74 | KCNK3 (0.80) | MEN1KMT2AMAPTRXFP1KCNK3 | |
| SCHEMBL5666088 | 0.73 | MEN1 (0.69) | MEN1KMT2AMAPTSMN1; SMN2KCNK3 | |
| SCHEMBL5536053 | 0.73 | ALDH1A1 (0.48) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12763862 | 0.71 | KCNK3 (0.75) | MEN1KMT2AMAPTRXFP1KCNK3 | |
| SCHEMBL11432595 | 0.71 | MEN1 (0.61) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11430463 | 0.70 | MEN1 (0.69) | MEN1KMT2AMAPTSMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928843-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007024754-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | AMGEN INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | TIE1, KDR, BDKRB2 | MEN1 2035/4885KMT2A 577/4885MAPT 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.